# Prospective clinical study of R-CMD therapy for indolent B cell lymphoma and mantle cell lymphoma from the Hokuriku Hematology Oncology Study Group

## TL;DR

This study evaluated the effectiveness and safety of R-CMD therapy for treating indolent B cell lymphoma and mantle cell lymphoma, showing promising results with high response rates.

## Contribution

The study provides new evidence on the efficacy of R-CMD therapy for indolent B cell lymphoma and mantle cell lymphoma in a prospective clinical setting.

## Key findings

- 26 out of 33 patients achieved complete or unconfirmed complete response to R-CMD therapy.
- R-CMD therapy was found to be relatively convenient and effective for treating indolent B cell lymphoma and mantle cell lymphoma.
- Four patients relapsed after remission, highlighting the need for continued monitoring and infection prevention.

## Abstract

Standardized treatments for indolent B cell lymphoma primarily consisting of follicular lymphoma (FL) and for mantle cell lymphoma (MCL) have yet to be established. Here the Hokuriku Hematology Oncology Study Group conducted a multicenter prospective study to investigate the efficacy and safety of a combination regimen of rituximab, cladribine, mitoxantrone, and dexamethasone (R-CMD) in indolent B cell lymphoma and MCL. A total of 33 CD20-positive patients who received care between January 2008 and August 2011 were investigated. These patients’ illnesses were FL (n = 21), nodal marginal zone B cell lymphoma (NMZB, n = 3), MCL (n = 3), splenic marginal zone B cell lymphoma (n = 2), hairy cell leukemia (n = 1), Waldenstrom macroglobulinemia (WM, n = 1), and lymphoplasmacytic lymphoma (LPL, n = 2). Patients received four 21-day cycles of rituximab 375 mg/m2 (day 1), cladribine 0.10 mg/kg (days 1–3), mitoxantrone 8 mg/m2 (day 1), and dexamethasone 8 mg/body (days 1–3), with four additional rituximab doses at 4-week intervals. Of the 33 patients, 26 achieved complete response/unconfirmed complete response, and six achieved a partial response (4 with FL, 1 with NMZB, 1 with WM). One had progressive disease (FL), and four relapsed after remission (1 with FL, 2 with MCL, 1 with LPL). R-CMD therapy was relatively convenient and effective in indolent B cell lymphoma and MCL. Nonetheless, to suppress the number and function of both B cells and T cells, comprehensive infection prevention and follow-up are necessary in the future.